Aarti Drugs posts Q1 FY26 PAT higher at Rs. 54 Cr
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
Longer-term follow up in the FLAURA2 Phase III trial confirms the favourable benefit-risk profile of this combination
Neuberg group commits to invest over Rs. 100 crores to start diagnostics facilities across Jharkhand in the next 2-3 years
The new Zigly center features and offers comprehensive veterinary services
Phosphate-based excipients provide higher bulk densities and enable the reduction of the tablet sizes
Plant-based chemistries have an outsized role to play for the HPC sector by meeting demand for good, gentle, and green products
The campaign celebrates radiant, healthy skin that shines naturally, empowering women to step forward with confidence in every walk of life.
Milestone also announced the extension of its $75 million Royalty Purchase Agreement with RTW Investments
Finerenone significantly reduced the combined risk of cardiovascular death and total (first and recurrent) heart failure events,
The agreement includes plans for distribution, technology transfer, local manufacturing, new pharmaceutical product development
Subscribe To Our Newsletter & Stay Updated